Quarterly ResultAug 12, 2026, 07:33 AM
Arbutus Receives $178M Moderna Payment, Plans $230M Buyback
AI Summary
Arbutus Biopharma reported its second quarter 2026 financial results and provided a corporate update. The company received $178.4 million in July from its settlement with Moderna and plans to return up to $230 million to shareholders through share repurchases. Additionally, Arbutus filed three international patent enforcement lawsuits against Pfizer and BioNTech related to its LNP technology and achieved FDA alignment on a Phase 2b clinical trial design for imdusiran. For Q2 2026, the company reported a net loss of $5.1 million on $1.0 million in revenue.
Key Highlights
- Received $178.4M from Moderna settlement in July 2026.
- Plans to return up to $230M in capital to shareholders via share repurchases.
- Filed three international patent enforcement lawsuits against Pfizer and BioNTech.
- Achieved FDA alignment for imdusiran Phase 2b clinical trial design.
- Q2 2026 net loss was $5.1M, or $(0.03) per basic and diluted common share.
- Q2 2026 total revenue was $1.0M, down from $10.7M in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $92.6M as of June 30, 2026.
Price Impact
More from ABUS